{
  "symbol": "LLY",
  "year": 2024,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1161,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.155
  },
  "top_positive": [
    {
      "sent": "Fair Value of Risk-Management Instruments The following table summarizes certain fair value information at September\u00a030, 2024 and December\u00a031, 2023 for risk management assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2024 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other current liabilities $ ( 2.0 ) $ \u2014 $ ( 2.0 ) $ \u2014 $ ( 2.0 ) Other noncurrent liabilities ( 71.8 ) \u2014 ( 71.8 ) \u2014 ( 71.8 ) Cross-currency interest rate contracts designated as net investment hedges: Other current liabilities ( 37.2 ) \u2014 ( 37.2 ) \u2014 ( 37.2 ) Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 68.0 \u2014 68.0 \u2014 68.0 Foreign exchange contracts designated as net investment hedges: Other current liabilities ( 126.8 ) \u2014 ( 126.8 ) \u2014 ( 126.8 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 22.9 \u2014 22.9 \u2014 22.9 Other current liabilities ( 14.7 ) \u2014 ( 14.7 ) \u2014 ( 14.7 ) Contingent consideration liabilities: Other noncurrent liabilities ( 32.0 ) \u2014 \u2014 ( 32.0 ) ( 32.0 ) 26 Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2023 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other current liabilities $ ( 2.4 ) $ \u2014 $ ( 2.4 ) $ \u2014 $ ( 2.4 ) Other noncurrent liabilities ( 100.3 ) \u2014 ( 100.3 ) \u2014 ( 100.3 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 291.2 \u2014 291.2 \u2014 291.2 Cross-currency interest rate contracts designated as net investment hedges: Other current liabilities ( 28.4 ) \u2014 ( 28.4 ) \u2014 ( 28.4 ) Other noncurrent liabilities ( 3.5 ) \u2014 ( 3.5 ) \u2014 ( 3.5 ) Cross-currency interest rate contracts designated as cash flow hedges: Other receivables 113.8 \u2014 113.8 \u2014 113.8 Other noncurrent assets 63.1 \u2014 63.1 \u2014 63.1 Foreign exchange contracts designated as hedging instruments: Other current liabilities ( 115.8 ) \u2014 ( 115.8 ) \u2014 ( 115.8 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 129.6 \u2014 129.6 \u2014 129.6 Other current liabilities ( 55.9 ) \u2014 ( 55.9 ) \u2014 ( 55.9 ) Contingent consideration liabilities: Other current liabilities ( 39.5 ) \u2014 \u2014 ( 39.5 ) ( 39.5 ) Other noncurrent liabilities ( 64.4 ) \u2014 \u2014 ( 64.4 ) ( 64.4 ) Risk-management instruments above are disclosed on a gross basis.",
      "score": 0.9933
    },
    {
      "sent": "21 Fair Value of Investments The following table summarizes certain fair value information at September\u00a030, 2024 and December\u00a031, 2023 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2024 Cash equivalents (2) $ 1,850.5 $ 1,850.5 $ 1,842.7 $ 7.8 $ \u2014 $ 1,850.5 Short-term investments: U.S.",
      "score": 0.9853
    },
    {
      "sent": "21 Fair Value of Investments The following table summarizes certain fair value information at September\u00a030, 2024 and December\u00a031, 2023 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2024 Cash equivalents (2) $ 1,850.5 $ 1,850.5 $ 1,842.7 $ 7.8 $ \u2014 $ 1,850.5 Short-term investments: U.S.",
      "score": 0.9853
    }
  ],
  "top_negative": [
    {
      "sent": "Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.",
      "score": -0.7845
    },
    {
      "sent": "Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.",
      "score": -0.7845
    },
    {
      "sent": "Various risks and uncertainties, including those discussed in \"Forward-Looking Statements\" in this Quarterly Report on Form 10-Q and \"Risk Factors\" in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December\u00a031, 2023, may cause our actual results, financial position, and cash generated from operations to differ from these forward-looking statements.",
      "score": -0.6808
    }
  ],
  "forward_snippets": [
    "The following include some but not all of the factors that could cause actual results or events to differ from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and uncertain outcome of acquisitions and business development transactions and related costs; \u2022 intense competition affecting our products, pipeline, or industry; \u2022 market uptake of launched products and indications; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; \u2022 safety or efficacy concerns associated with our products; \u2022 dependence on relatively few products or product classes for a significant percentage of our total revenue and an increasingly consolidated supply chain; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and biosimilar products, and risks from the proliferation of counterfeit or illegally compounded products; \u2022 our ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; \u2022 information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data and violations of data protection laws or regulations; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the use of artificial intelligence or other emerging technologies in various facets of our operations which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; \u2022 the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade disruptions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; \u2022 fluctuations in foreign currency exchange rates or changes in interest rates and inflation; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or activities; \u2022 changes in tax law and regulation, tax rates, or events that differ from our assumptions related to tax positions; \u2022 regulatory changes and developments; \u2022 regulatory actions regarding our operations and products; \u2022 regulatory compliance problems or government investigations; \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; \u2022 asset impairments and restructuring charges; and \u2022 changes in accounting and reporting standards.",
    "We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2025.",
    "We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2024.",
    "We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2024.",
    "Note\u00a03: Acquisitions We engage in various forms of business development activities to enhance or refine our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements."
  ]
}